Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

Roger Li; Philippe E Spiess; Scott M Gilbert; Andrea Necchi

doi:10.1016/j.eururo.2019.02.027

Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer

Eur Urol. 2019 Jul;76(1):4-6. doi: 10.1016/j.eururo.2019.02.027. Epub 2019 Mar 2.

Authors

Roger Li¹, Philippe E Spiess², Scott M Gilbert², Andrea Necchi³

Affiliations

¹ Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Electronic address: [email protected].
² Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
³ Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 30833139
DOI: 10.1016/j.eururo.2019.02.027

Abstract

It has been demonstrated that immune checkpoint blockade has efficacy similar to chemotherapy in the neoadjuvant setting. Biomarkers such as PD-L1 expression levels can be used to rationally design clinical trials aimed at personalizing systemic therapy for patients with muscle-invasive bladder cancer.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / genetics
Cystectomy
Humans
Mutation
Neoadjuvant Therapy*
Neoplasm Invasiveness
Precision Medicine
Tumor Microenvironment
Urinary Bladder Neoplasms / genetics
Urinary Bladder Neoplasms / pathology
Urinary Bladder Neoplasms / therapy*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
atezolizumab
pembrolizumab